Clinical trials: Pre-Diabetes
Elevated Body Mass Index
Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index
A 12-week study to assess LIK066 effect on body weight in diabetics, prediabetics and normoglycemic patients with elevated body mass index (BMI)
- Trial name
- NCT02470403
- Testing
- LIK066
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
PreDiabetes
Prevention of Diabetes Using Mobile-enabled, Virtual Delivery of the National Diabetes Prevention Program
This study will test the weight loss efficacy of a mobile diabetes prevention program intervention. Half of the sample of prediabetic adults will receive the virtual DPP and half will receive usual medical care.
- Trial name
- NCT03865342
- Testing
- Noom Coach DPP
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- Noom Inc.
Prediabetic State, Overweight
OXXYNEA® GS: Study for Glycaemia Management
The aim of this study is to develop a proof of concept establishing a causal relationship between glycemia improvement through combination of polyphenols-rich botanical extracts or polyphenols-rich botanical extracts associated…
- Trial name
- NCT05926947
- Testing
- Verum A, Verum B
- Where
- Spain
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Fytexia
Healthy, Prediabetic State (IGT)
Noninvasive Transcutaneous Glucometer Development
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
- Conditions
- Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT01168076
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Type 2 Diabetes
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD
This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once…
- Trial name
- NCT06558708
- Testing
- GZR101 Injection, GZR33 Injection, Insulin aspart
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus
Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the Experimental Device
The study is an open-label, randomized, two-period, one-way crossover study using the Meal Tolerance Test (MTT) protocol or the daily life setting protocol. The study consists of two parts.
- Trial name
- NCT02306343
- Testing
- InsuPad
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Insuline Medical Ltd.
Pre Diabetes
Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome
According to the International Diabetes Federation, one in every 12 individuals is a diabetic (about 8% of the world population).
- Trial name
- Glucogold (NCT02834078)
- Testing
- BGG
- Volunteers
- 126 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Impaired Glucose Tolerance
GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.
- Trial name
- NCT01468376
- Testing
- GLU-01, GLU-02, GLU-03
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc
Diabetes, Pre-diabetes
Does Insulin Requirement Post Cardiac Surgery Predicts The Risk Of Developing Diabetes
The patient outcome in cardiac surgery is substantially linked to the occurrence of hyperglycemia. Qatar ranks 5th in the rate of diabetes globally; Moreover diabetics comprise more than 40% of patients admitted to the cardiac…
- Trial name
- NCT04765982
- Testing
- Checking diabetes development in follow up at 3 month
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Diabetes Mellitus, Type 2
Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes
The purpose of this study is to compare Lispro Mixture Therapy (insulin lispro 50/50 given three times daily with meals) to Glargine Basal-Bolus Therapy (insulin glargine daily with the addition of insulin lispro given three…
- Trial name
- NCT00110370
- Testing
- Lispro Mixture Therapy, Glargine Basal-Bolus Therapy
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Low Glycemic Index (GI) Food, Pre Diabetes
Determination of the Glycemic Index Values of 10 Cereal-based Products
To determine the Glycemic index values for 10 cereal-based products
- Conditions
- Low Glycemic Index (GI) Food, Pre Diabetes, Diabetes
- Trial name
- NCT06710743
- Testing
- Glucose solution Day 1, Day 8, and Day 15, Food (cereal). Ten different cereals served once each
- Where
- Australia
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Type 2 Diabetes
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
In recent years, with the further research of the pathogenesis of diabetes mellitus and the mechanism of oral antidiabetes drugs, the early combination therapy of oral antidiabetes drugs and insulin is getting paid more and more…
- Trial name
- CODMS (NCT00736515)
- Testing
- Gliclazide MR and Insulin Glargine Injection, Biosynthetic Human Insulin Injection
- Where
- 8 sites in China
- Volunteers
- 160 people
- Sponsor
- Servier (Tianjin) Pharmaceutical Co. LTD.
Pre-diabetes, Undiagnosed Diseases
A Pivotal Clinical Investigation Confirming the Safety and Accuracy of the Glyconics-DS in Assessment of Glycated Nail Keratin in Individuals With Unknown Diabetes Status and Performance Evaluation of the Glyconics SW Package
The main clinical study objective is to confirm the accuracy of the Glyconics-DS spectrometer when used in its intended medical purpose population, i.e., in individuals with unknown diabetes risk.
- Trial name
- ANODE03 (NCT06261944)
- Testing
- Near-infrared (NIR)
- Where
- Spain
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- Glyconics Ltd
Metabolic Syndrome (MetS), Inflammation
Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults
This randomized study will be conducted to compare the effect of a healthy beef-centric diet to a healthy U.S.-style dietary pattern on inflammation and other metabolic health outcomes in a metabolic syndrome and/or pre-diabetic…
- Conditions
- Metabolic Syndrome (MetS), Inflammation, Pre-Diabetes
- Trial name
- NCT07269847
- Testing
- Healthy Beef-Centric Diet, Healthy U.S.-Style Dietary Pattern
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- National Cattlemen's Beef Association, a contractor to the Beef Checkoff
Type 2 Diabetes Mellitus
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
Primary Objective: To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24) Secondary Objective: To assess the effect of the 2 lixisenatide regimens on: The…
- Trial name
- NCT01517412
- Testing
- Lixisenatide (AVE0010), Self-injector pen device (OptiClik®), Metformin
- Where
- 82 sites in United States, Canada and 8 more
- Volunteers
- 451 people
- Sponsor
- Sanofi
Pre Diabetic
A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome
This study aims to investigate the effect of a cobiotic formulation, prepared as a smoothie beverage, on the ratio of intestinal microbiota of the Bacteroidetes phylum to those of the Firmicutes phylum in the stool as well as the…
- Trial name
- NCT01724736
- Testing
- NM504:
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NuMe Health
Normoglycemia, Prediabetes
Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes
The goal of this clinical trial is to investigate the safety and efficacy of Nextida GC-B on glycemic control in adults with normoglycemia and prediabetes.
- Conditions
- Normoglycemia, Prediabetes, Glycemic Control
- Trial name
- NCT07149064
- Testing
- Nextida GC-B
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 3 (NCT04795531)
- Testing
- Insulin icodec, Insulin degludec
- Where
- 190 sites in United States, Argentina and 10 more
- Volunteers
- 588 people
- Sponsor
- Novo Nordisk A/S
Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
The main purpose of the study is to check: Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or…
- Conditions
- Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
- Trial name
- PreTreg (NCT06688331)
- Testing
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab)
- Where
- 9 sites in Poland
- Volunteers
- 150 people
- Sponsor
- PolTREG S.A.
Impaired Glucose Tolerance
HSK7653 in Chinese Patients with Impaired Glucose Tolerance
This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.
- Trial name
- NCT04727580
- Testing
- HSK7653 10mg Q2W, HSK7653 25mg Q2W
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.